Formulation and in vitro and in vivo availability of diclofenac sodium enteric-coated beads

• Published in: Drug development and industrial pharmacy Vol. 24; no. 7; p. 661
• Main Authors: Hosny, E A, el-Mahrouk, G M, Gouda, M W
• Format: Journal Article
• Language: English
• Published: England 01.01.1998
• Subjects: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal - pharmacokinetics; Biological Availability; Chemistry, Pharmaceutical; Diclofenac - pharmacokinetics; Dogs; Male; Microspheres; Tablets, Enteric-Coated
• ISSN: 0363-9045
• DOI: 10.3109/03639049809082368

Diclofenac sodium enteric-coated beads were prepared using the conventional pan coating technique. Eudragit L100 was used as a pH-dependent release-controlling polymer. The beads were evaluated for their particle size distribution, drug loading efficiency, flowability, in vitro release in 0.1 N HCl (pH 1.2) and phosphate buffer (pH 6.8), and bioavailability in beagle dogs relative to the commercial enteric-coated tablets Voltaren. The beads showed a narrow particle size distribution in which 83% of the beads were in the range of 1-2 mm. The actual yield of the beads was 90.5% and their drug loading was 92%. The beads released about 8% of the drug during 2 hr of dissolution in 0.1 N HCl, and the commercial tablets released no drug. In phosphate buffer (pH 6.8) both formulations released their drug content in 1 hr. Both formulations are, therefore, in compliance with the USP requirements for release from enteric-coated dosage forms. The in vivo availability study in six beagle dogs revealed that the formulated enteric-coated beads filled in hard gelatin capsules had a 197.54% bioavailability relative to that of the commercial Voltaren tablets. The tablets showed a significantly lower (p < 0.05) area under curve for 0-8 hr (AUC0-8 hr) of 13.44 +/- 15.02 micrograms hr/ml compared to 26.55 +/- 5.19 micrograms hr/ml for the capsules. The capsules showed a nonsignificantly (p > 0.05) higher peak plasma concentration (Cmax) of 6.77 +/- 0.67 micrograms/ml compared to 5.88 +/- 7.38 micrograms/ml for the tablets. The time to reach peak (Tmax) values were 2 +/- 1.48 and 2.25 +/- 1.08 hr for the capsules and tablets, respectively. The capsules showed less interdog variability with respect to Cmax (CV% 34.6) and AUC (CV% 19.55) compared to CV% 79.9 and 111.76, respectively, for the commercial tablets.